info@seagull-health.com
SeagullHealth
语言:
search

Cerezyme(Imiglucerase)

Names
伊米苷酶,思而赞,依米格西酶,注射用伊米苷酶
Indicatons
Patients diagnosed with Type 1 and Type 3 Gaucher disease exhibiting non-neurological symptoms.
Price:
Manufacturer:
Sanofi
Dosage form:
INJECTION
Validity period:
36 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Cerezyme(Imiglucerase) Instructions:Uses,Dosage, Side Effects

Cerezyme (imiglucerase) is a recombinant enzyme therapy used to treat Gaucher disease, a rare lysosomal storage disorder caused by β-glucocerebrosidase deficiency. By replacing the missing enzyme, Cerezyme facilitates the breakdown of accumulated glucocerebroside, alleviating symptoms such as hepatosplenomegaly, anemia, and bone abnormalities.

This medication is administered through intravenous infusion and is tailored to individual patient needs. It has demonstrated efficacy in improving hematological and visceral symptoms, providing a crucial therapeutic option for managing the disease long-term. Due to its specialized nature, Cerezyme is typically used under the supervision of healthcare professionals in hospital or clinical settings.

Generic name
Cerezyme(Imiglucerase)
English name
Imiglucerase
Alternative Names
伊米苷酶,思而赞,依米格西酶,注射用伊米苷酶
Drug prices
Indications

Imiglucerase for Injection is indicated for long-term enzyme replacement therapy in patients diagnosed with non-neuropathic (Type I) and chronic neuropathic (Type II) Gaucher disease who have significant clinical manifestations of non-neurological lesions.

The clinical manifestations of non-neurological lesions in Gaucher disease include one or more of the following conditions:

1. Anemia excluding that caused by other reasons, such as iron deficiency anemia.

2. Thrombocytopenia.

3. Bone disease excluding that caused by other reasons, such as vitamin D deficiency.

4. Hepatomegaly or splenomegaly.

Therapeutic Target
Mechanism: Targets β-glucocerebrosidase deficiency in lysosomes, hydrolyzing accumulated glucocerebroside into glucose and ceramide.
Active Ingredients
Active Ingredient: Imiglucerase (recombinant human β-glucocerebrosidase analog).
Dosage Form
INJECTION
Specifications
400 units/vial
Dosage and Administration

Dosing

Range: 2.5 units/kg thrice weekly to 60 units/kg every 2 weeks.

Titration: Adjust based on disease severity and therapeutic goals.

Administration Protocol

Reconstitution:

Add 10.2 mL Sterile Water to each 400-unit vial; roll/tilt to dissolve (avoid shaking).

Final concentration: 40 units/mL.

Dilution:

Dilute with 0.9% NaCl to 100–200 mL (100 mL for patients <18 kg).

Infusion:

≥18 kg: 1–2 hours.

<18 kg: 2 hours.

Filtration: Use in-line 0.2 μm filter if needed.

Premedication

For hypersensitivity-prone patients: Antihistamines/corticosteroids.

    Recommended articles
    Related articles
    How to Alleviate the Side Effects of Imiglucerase
    Imiglucerase, also known as Cerezyme, is a recombinant glucocerebrosidase analog specifically designed for the treatment of type 1 Gaucher disease. It can effectively catalyze the hydrolysis of glucoc...
    Cerezyme(Imiglucerase):Clinical Uses, Recommended Dosage, Treatment Effect
    Imiglucerase (Cerezyme) is an enzyme replacement therapy used for the treatment of Gaucher disease. Gaucher disease is a genetic disorder primarily caused by a deficiency of the enzyme acid β-glucosid...
    Precautions for Imiglucerase (Cerezyme)
    The use of imiglucerase should be carried out under the supervision of a professional doctor. Doctors will formulate an individualized treatment plan based on the specific conditions of patients and a...
    Dosage and Administration of Imiglucerase (Cerezyme)
    Imiglucerase is administered by intravenous injection. This is usually performed by professional medical personnel in medical institutions. The specific dosage will be determined based on the patient&...
    What are the purchasing channels for Imiglucerase?
    Imiglucerase, also known as Cerezyme, is suitable for adult patients and children with type 1 Gaucher disease aged 2 years and above, and it is an important drug for the treatment of type 1 Gaucher di...
    What is the latest price of imiglucerase in 2025?
    Imiglucerase is a key drug for the treatment of type 1 Gaucher disease, and its price has always been a concern for patients. In 2025, the price of imiglucerase has undergone certain adjustments. Pati...
    New Drugs
    Infigratinib(Truseltiq)
    Infigratinib(Truseltiq)
    Treatment of previously treated, unresectable locally advanced or metastatic...
    Opicapone(Ongentys)
    Opicapone(Ongentys)
    Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
    Deflazacort(Emflaza)
    Deflazacort(Emflaza)
    Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
    Faricimab-svoa(Vabysmo)
    Faricimab-svoa(Vabysmo)
    Treatment of neovascular age-related macular degeneration, diabetic macular...
    Counselling Service
    Global Drug Search
    Clinical Research Recruitment
    Overseas Medical Treatment
    Remote Consultations
    Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
    Submit
    Business
    • Core products
    • Antitumor drugs
    • General drug
    • Antiviral drugs
    • Biological agents
    Contact Us 
    • mailbox:info@lucius.la
    Welcome to consult
    ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved